Table 1.
Exposure | First Author | Study type | Cohort | Outcome | Risk of exposure | # RA cases | Reference |
---|---|---|---|---|---|---|---|
Cigarette Smoking | Di Giuseppe | Meta-analysis (3 prospective cohorts, 7 case-control) | Multiple | RF +/- RA | Ever smoking: RF+ RA RR 2.47, RF- RA RR 1.58 | 4552 | (28) |
Cigarette Smoking | Hedstrom | Case-Control | Sweden (EIRA) | ACPA +/- RA | Ever smoking: ACPA+ RA OR 1.9, ACPA- RA OR 1.3 | 3655 | (29) |
Cigarette Smoking | Too | Case-Control | Malaysia (MyEIRA) | ACPA +/- RA | Ever smoking: ACPA+ RA OR 4.1 | 1076 | (30) |
Cigarette Smoking | Bang | Case-Control | Korea | RA | Ever smoking: RA OR 2.7 | 1482 | (31) |
Cigarette Smoking | Pederson | Case-Control | Denmark | ACPA +/- RA | Ever smoking: ACPA+ RA OR 1.22 to 57.4; stratified by pack-year exposure AND SE+/- | 515 | (32) |
Cigarette Smoking | Kochi | Case-Control | Japan | RA | Ever smoking: RA OR 1.15 to 1.35 | 2015 | (33) |
Cigarette Smoking | Karlson | Retrospective Cohort | USA (Women’s Health Cohort) | RA | Ever smoking: RA RR 1.10 to 1.32; stratified by pack-year | 7697 | (25) |
Cigarette Smoking | Costenbader | Retrospective Cohort | USA (Nurses Health Study) | RA | Ever smoking: RA RR 1.47 | 680 | (26) |
Cigarette Smoking | Di Giuseppe | Retrospective Cohort | Sweden (Swedish Mammography Cohort) | RA | Ever smoking: RA RR 2.31 | 219 | (27) |
Cigarette Smoking | de Hair | Prospective Cohort | Netherlands (IgM RF or ACPA + at-risk) | RA | Ever smoking: Sero+ RA HR 9.6 | 15 | (34) |
Cigarette Smoking | Ponchel | Prospective Cohort | United Kingdom (Leeds; RF or ACPA+ with joint pain) | RA | Ever smoking: Sero+ RA OR 3.1 | 125 | (35) |
ACPA, anti-citrullinated protein antibodies; RF, Rheumatoid Factor; EIRA, Epidemiological Investigation of Rheumatoid Arthritis; RR, Relative Risk; OR, Odds Ratio; HR, Hazards Ratio. All RR/OR/HR are statistically significant unless otherwise stated.